Rehan Qayyum, MD; Shari Bolen, MD, MPH; Nisa Maruthur, MD, MHS; Leonard Feldman, MD; Lisa M. Wilson, ScM; Spyridon S. Marinopoulos, MD, MBA; Padmini Ranasinghe, MD, MPH; Muhammed Amer, MD; Eric B. Bass, MD, MPH
Evidence comparing premixed insulin analogues (a mixture of rapid-acting and intermediate-acting insulin analogues) with other antidiabetic agents is urgently required to guide appropriate therapy.
To summarize the English-language literature on the effectiveness and safety of premixed insulin analogues compared with other antidiabetic agents in adults with type 2 diabetes.
The authors searched MEDLINE, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials from inception to February 2008 and sought unpublished data from the U.S. Food and Drug Administration, European Medicines Agency, and industry.
Studies with control groups that compared premixed insulin analogues with another antidiabetic medication in adults with type 2 diabetes.
2 reviewers using standardized protocols performed serial abstraction.
Evidence from clinical trials was inconclusive for clinical outcomes, such as mortality. Therefore, the review focused on intermediate outcomes. Premixed insulin analogues were similar to premixed human insulin in decreasing fasting glucose levels, hemoglobin A1c levels, and the incidence of hypoglycemia but were more effective in decreasing postprandial glucose levels (mean difference, âˆ’1.1 mmol/L; 95% CI, âˆ’1.4 to âˆ’0.7 mmol/L [âˆ’19.2 mg/dL; 95% CI, âˆ’25.9 to âˆ’12.5 mg/dL]). Compared with long-acting insulin analogues, premixed insulin analogues were superior in decreasing postprandial glucose levels (mean difference, âˆ’1.5 mmol/L; CI, âˆ’1.9 to âˆ’1.2 mmol/L [âˆ’27.9 mg/dL; CI, âˆ’34.3 to âˆ’21.5 mg/dL]) and hemoglobin A1c levels (mean difference, âˆ’0.39% [CI, âˆ’0.50% to âˆ’0.28%]) but were inferior in decreasing fasting glucose levels (mean difference, 0.7 mmol/L; CI, 0.3 to 1.0 mmol/L [12.0 mg/dL; CI, 6.0 to 18.1 mg/dL]) and were associated with a higher incidence of hypoglycemia. Compared with noninsulin antidiabetic agents, premixed insulin analogues were more effective in decreasing fasting glucose levels (mean difference, âˆ’1.1 mmol/L; CI, âˆ’1.7 to âˆ’0.6 mmol/L [âˆ’20.5 mg/dL; CI, âˆ’29.9 to âˆ’11.2 mg/dL]), postprandial glucose levels (mean difference, âˆ’2.1 mmol/L; CI, âˆ’3.4 to âˆ’0.8 mmol/L [âˆ’37.4 mg/dL; CI, âˆ’61.0 to âˆ’13.7 mg/dL]), and hemoglobin A1c levels (mean difference, âˆ’0.49% [CI, âˆ’0.86% to âˆ’0.12%]) but were associated with a higher incidence of hypoglycemia.
The literature search was restricted to studies published in English. Data on clinical outcomes were limited. The small number of studies for each comparison limited assessment of between-study heterogeneity.
Premixed insulin analogues provide glycemic control similar to that of premixed human insulin and may provide tighter glycemic control than long-acting insulin analogues and noninsulin antidiabetic agents.
The relative effects of premixed insulin analogues, other insulin regimens, and noninsulin antidiabetic agents for adults with type 2 diabetes are unclear.
This systematic review of comparative trials in adults with type 2 diabetes found that premixed insulin analogues and premixed human insulin provided similar glycemic control. Premixed analogues provided tighter glycemic control and caused more hypoglycemia than long-acting insulin analogues and noninsulin antidiabetic agents.
Evidence for effects on clinical outcomes was scant and inconclusive.
We need large, long-term trials that compare premixed insulin analogues with other agents to see whether improvements in glucose control lead to improved clinical outcomes.
FDA = U.S. Food and Drug Administration.
* The total may exceed the number in the corresponding box because articles could be excluded for more than 1 reason at this level.
Error bars represent 95% CIs. To convert glucose values to mmol/L, multiply by 0.0555.
* Pooled results include those of a study (43) that administered insulin lispro 50/50 in the morning and afternoon and insulin lispro 75/25 in the evening.
† Pooled results include those of a study (55) that administered insulin lispro 50/50 in the morning and insulin lispro 75/25 in the evening.
‡ Reference 21 was excluded.
† Reference 21 was excluded.
Error bars represent 95% CIs.
* Combined outcome includes all-cause mortality and cardiovascular morbidity.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson LM, Marinopoulos SS, et al. Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes. Ann Intern Med. 2008;149:549-559. doi: 10.7326/0003-4819-149-8-200810210-00242
Download citation file:
Published: Ann Intern Med. 2008;149(8):549-559.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, High Value Care.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only